June 25, 2022

MegaRobo, an clever existence science endeavor, has introduced its of entirety of C-round financing totaling $300 million. The investment used to be collectively led through Goldman Sachs Asset Control LP, Asia Funding Capital and GGV Capital, with endured funding from present shareholder Sinovation Ventures. It used to be additionally adopted through Singapore’s Pavilion Capital, Starr Capital, U-MEMBER, Redview Capital, Harvest Capital and Taihecap. Moreover, a number one home endeavor within the box of biotechnology participated on this around of financing.

The raised finances will reportedly be used to deepen the company’s R&D funding within the box of clever automation in existence sciences. The company can even actively increase trade and boost up its internationalization procedure.

Based in 2016, MegaRobo supplies the existence science trade with absolutely computerized answers, starting from easy console workflow automation to complicated steps in large-scale gadget procedure programs. It additionally extends to the following era of existence science infrastructure and techniques that advertise the R&D of AI medicine.

The company’s automation workflow integrates AI instrument, analytical tools, laboratory {hardware} and check consumables right into a unmarried laboratory gadget. When put next with the normal laboratory gadget, the company can succeed in upper potency and extra strong experimental leads to more than a few existence science utility fields, reminiscent of antibody variety, cellular line building and molecular screening, which has been presented and put into use in many nations around the globe.

SEE ALSO: Wissen Secures $10M in Pre-A+ Financing

MegaRobo makes a speciality of development an infrastructure known as “Kunpeng Laboratory.” It carries out in-depth strategic cooperation with many main enterprises within the box of existence sciences, builds infrastructure and platforms to optimize R&D potency, and actively explores existence science analysis.

See also  Device Imaginative and prescient Company NeuroBot Completes Sequence A Financing

The previous decade has witnessed an expanding quantity of small and medium-sized biotechnology corporations, the sped up help of capital and the increasing trade scale within the Asia-Pacific area. This has additionally promoted the fast building up of R&D funding within the box of existence sciences. Potency growth and useful resource optimization have change into the core issues to be solved within the building of the trade, and clever automation is an inevitable technique to this problem.